Denali Therapeutics Inc. Common Stock

DNLINASDAQ

Healthcare · Biological Products, (no Diagnostic Substances)

Market cap

$3.21B

Employees

507

Exchange

NASDAQ

Headquarters

SOUTH SAN FRANCISCO, CA

About Denali Therapeutics Inc. Common Stock

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Industry

Biological Products, (no Diagnostic Substances)

Sector

Healthcare

Country

US

Website

www.denalitherapeutics.com